GLP-2 Grows Intestinal Tissue — But Could It Also Promote Intestinal Tumors?

Narrative review based on PubMed literature searches using English keywords. The authors reviewed all published experimental (animal) and clinical (human) studies examining GLP-2's relationship to intestinal neoplasia. The review covers both the growth-stimulating mechanisms of GLP-2 and the available safety data from clinical use of teduglutide.

Teduglutide (a GLP-2 analog) is an FDA-approved treatment for short bowel syndrome, a life-threatening condition where patients cannot absorb enough nutrition. The drug works by stimulating intestinal tissue growth — but this same growth-promoting property raises a critical safety question: could it also promote intestinal cancers? This review highlights a real clinical dilemma where a drug that provides essential benefit for one condition could theoretically increase risk of another. Patients on long-term teduglutide need monitoring, and the field needs better long-term safety data.

This review highlights a fundamental tension in growth factor therapy — the same biological properties that make a peptide therapeutic (stimulating tissue growth) can also raise cancer concerns. This pattern appears across multiple peptide classes, from growth hormone to IGF-1 to GLP-2. The GLP-2 cancer question is particularly relevant because teduglutide patients often need treatment for years or even life. As GLP-2 biology becomes better understood, the field needs long-term registry data to definitively answer whether this theoretical risk becomes a practical one.

The studies on GLP-2 and intestinal neoplasia are described as 'sparse,' limiting the strength of conclusions. The rodent tumor data may not directly translate to humans. Clinical safety data extends only to 30 months. As a narrative rather than systematic review, study selection may not be comprehensive. The review cannot establish causation between GLP-2 treatment and cancer risk in humans.